A phase 2A open-label, multicenter trial of the safety and efficacy of LYC-55716, a first-in-class oral, small-molecule RORγ agonist to treat select solid tumors.


Conference Paper

Full Text

Duke Authors

Cited Authors

  • Kelly, K; Johnson, ML; Mahalingam, D; Liu, SV; Uronis, HE; Wu, C; Carter, L; Hu, X; Weems, GA; Wilkins, HJ; Duska, LR

Published Date

  • May 20, 2018

Published In

Volume / Issue

  • 36 / 15_suppl

Start / End Page

  • TPS2617 - TPS2617

Published By

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

International Standard Serial Number (ISSN)

  • 0732-183X

Digital Object Identifier (DOI)

  • 10.1200/jco.2018.36.15_suppl.tps2617